NASDAQ:FHTX Foghorn Therapeutics Q2 2025 Earnings Report $3.52 0.00 (0.00%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$3.57 +0.05 (+1.53%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Foghorn Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS -$0.31Beat/MissBeat by +$0.03One Year Ago EPSN/AFoghorn Therapeutics Revenue ResultsActual Revenue$7.56 millionExpected Revenue$7.62 millionBeat/MissMissed by -$60.00 thousandYoY Revenue GrowthN/AFoghorn Therapeutics Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time7:00AM ETUpcoming EarningsFoghorn Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 2, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Foghorn Therapeutics Earnings HeadlinesFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 27 at 2:15 AM | americanbankingnews.comH.C. Wainwright Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)August 21, 2026 | theglobeandmail.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 30 at 1:00 AM | Stansberry Research (Ad)Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate UpdateAugust 6, 2026 | globenewswire.comStep Pharma announces the appointment of Neil Gallagher as Non-Executive DirectorJuly 1, 2026 | globenewswire.comFoghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comSee More Foghorn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email. Email Address About Foghorn TherapeuticsFoghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company develops medicines designed to regulate gene expression by targeting the chromatin regulatory system, a network of proteins and complexes that controls how genetic information is organized and used within cells. Foghorn’s discovery platform, known as Gene Traffic Control, is intended to identify drug targets within chromatin-remodeling complexes and develop selective small-molecule therapies. Its research has primarily focused on oncology, including cancers associated with abnormalities in chromatin regulators. The company has advanced investigational programs such as FHD-286, a small-molecule inhibitor designed to affect chromatin-remodeling ATPases, and FHD-609, a targeted protein degrader directed at the BRD9 protein. Founded in 2015, Foghorn has collaborated with pharmaceutical and biotechnology companies to pursue treatments based on its chromatin biology platform. The company’s drug candidates are investigational and have been evaluated in clinical studies for selected hematologic malignancies and solid tumors. Foghorn is led by President and Chief Executive Officer Adrian Gottschalk.View Foghorn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
